Urologic Oncology Articles

NICE Rejects Treatments for Bladder and Thyroid Cancer
The UK’s National Institute for Health and Care Excellence has issued guidelines recommending against nivolumab (Opdivo), lenvatinib (Lenvima), and sorafenib (Nexavar).
Steps Being Taken to Turn mRCC Into a Chronic Disease
Daniel M. Geynisman, MD, discusses remaining challenges in the landscape of RCC, despite progress with systemic therapies and the pivotal ongoing studies combining immunotherapy and targeted therapy.
Abiraterone Approaches EU Approval for Newly Diagnosed Hormone-Sensitive Prostate Cancer
The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanding the existing marketing authorization for abiraterone acetate (Zytiga) in men with newly diagnosed, high-risk metastatic hormone-sensitive prostate cancer.
FDA Grants Priority Review to Frontline Cabozantinib in RCC
The FDA has granted a priority review to a supplemental new drug application for cabozantinib (Cabometyx) for previously untreated patients with advanced renal cell carcinoma.
Revised Guidelines Helping to Advance Kidney Cancer Care
Robert G. Uzzo, MD, discusses recent guidelines that have impacted clinical practice and ongoing biomarker research in the field of kidney cancer.
Novel Immunotherapy Approaches Moving Through RCC Pipeline
Matthew R. Zibelman, MD, discussed the promise of immunotherapy combinations for patients with kidney cancer.
FDA Approval Sought for Apalutamide in Prostate Cancer
A new drug application has been submitted to the FDA for apalutamide (ARN-509) for the treatment of non-metastatic castration-resistant prostate cancer (CRPC).
Immunotherapy Agents Leading Advancements in Metastatic Bladder Cancer
The therapeutic landscape is rapidly being altered by clinical trials of immunotherapy for patients with metastatic urothelial carcinoma, but simply changing the way quality of life is monitored could provide dramatic improvements in overall survival.
Control of Non-Muscle Invasive Bladder Cancer Recurrence With TURBT and Beyond
The aim of treating NMIBC is avoid the loss of the bladder and to prevent recurrence and progression to muscle-invasive disease.
Expert Urges for a More Multidisciplinary Approach to Bladder Cancer Care
Robert Jones, MD, discusses the future treatment landscape for patients with urothelial carcinoma in a more multidisciplinary setting.
Publication Bottom Border
Border Publication